COMydAL Program
We are excited to welcome you to participate in the 1st World Congress on Controversies in MDS and AML (COMydAL), which will be held virtually over the days of September 22-23, 2022, in parallel with the 2022 IACH Meeting.
This inaugural program will bring to the forefront the latest and most controversial data and information in the field of MDS and AML, providing a unique opportunity for world-class leaders in the field to debate vital issues – thank you for joining!
| All presentations indicated with * were available for on demand viewing only until Monday, October 3, 2022 DAY 1 – AML |
|
| 13:15-13:25 | Welcome Address |
| 13:25-14:30 | Session 1 |
| Debate: Therapeutic decisions based on MRD in AML: Ready for prime time? | |
| * Yes: Christopher Hourigan, USA | |
| No: Christopher Gibson, USA | |
| Case studies of MRD use for therapeutic decisions in AML: Andrew Wei, Australia | |
| Panel discussion | |
| 14:30-15:35 | Session 2 |
| Debate: Which FLT3 inhibitor to use in frontline therapy in FLT3 mutated AML? | |
| Midostaurin: Richard Stone, USA | |
| Quizartinib: Harry Erba, USA | |
| Case studies of FLT3 inhibitors in AML: Selina Luger, USA | |
| Panel discussion | |
| 15:35-16:45 | Session 3 |
| Debate: Intensive chemotherapy or Ven-based lower intensity regimens for older FIT AML patients? | |
| * Intensive chemo: Jessica Altman, USA | |
| Non-intensive chemo: Nicholas Short, USA | |
| Case studies: Can we cease VEN-AZA in patients in long-term remission? Chong Chyn Chua, Australia | |
| Panel discussion | |
| 16:45-17:50 | Session 4 |
| Debate: Should we use maintenance therapy post allogeneic transplant in AML? | |
| * Yes: Lohith Gowda, USA | |
| No: Catherine Lai, USA | |
| Case studies of how I use maintenance therapies post alloBMT in AML: Asmita Mishra, USA | |
| Panel discussion | |
| 17:50-19:00 | Session 5 |
| Will immune checkpoint inhibition find a way in AML and MDS? Naval Daver, USA | |
| Will CAR therapies find a way in AML and MDS? Monica Guzman, USA | |
| Case studies: How I use immune therapies in AML and MDS: Ivana Gojo, USA | |
| Panel discussion | |
| 19:00-20:15 | Session 6 |
| Debate: In 10 years we will cure most AML patients without transplant | |
| *Yes: Tapan Kadia, USA | |
| No: Gail Roboz, USA | |
| * Case studies: How I decide on recommending alloBMT in AML: Michael Heuser, Germany | |
| Panel discussion | |
